(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Liberty Media, Acorda Therapeutics, and Coupons.com.

Rank Financial Asset Price Change Updated (EST)
1 Liberty Media (LSXMB) 46.01 11.38% 2022-11-25 13:23:38
2 Acorda Therapeutics (ACOR) 0.62 7.6% 2022-11-24 23:08:08
3 Coupons.com (COUP) 62.69 6.38% 2022-11-25 13:01:44
4 TherapeuticsMD (TXMD) 4.46 5.94% 2022-11-25 13:03:59
5 Celsius Holdings (CELH) 109.24 5.12% 2022-11-25 13:01:41
6 Biolase (BIOL) 1.01 4.64% 2022-11-25 15:13:06
7 Atlantic American Corporation (AAME) 2.98 4.56% 2022-11-24 21:11:06
8 Canopy Growth (CGC) 3.66 4.43% 2022-11-25 12:56:31
9 Allegiant Travel Company (ALGT) 80.62 4.42% 2022-11-25 03:14:07
10 Amedisys (AMED) 91.25 4.32% 2022-11-25 04:41:14

The three biggest losers today are ARC Group Worldwide, Bilibili, and AngioDynamics.

Rank Financial Asset Price Change Updated (EST)
1 ARC Group Worldwide (ARCW) 0.85 -9.57% 2022-11-25 07:17:07
2 Bilibili (BILI) 12.33 -7.15% 2022-11-25 13:07:54
3 AngioDynamics (ANGO) 13.61 -7.04% 2022-11-25 05:23:15
4 Futu Holdings (FUTU) 52.71 -6.51% 2022-11-25 13:02:15
5 Credit Suisse Group (CS) 3.59 -6.27% 2022-11-25 13:51:34
6 Assembly Biosciences (ASMB) 1.35 -5.59% 2022-11-25 07:47:15
7 Astrotech Corporation (ASTC) 0.34 -5.58% 2022-11-25 09:06:08
8 Momo (MOMO) 4.90 -5.41% 2022-11-25 13:13:20
9 JD.com (JD) 49.48 -5.32% 2022-11-25 13:12:52
10 Zai Lab (ZLAB) 31.72 -4.97% 2022-11-25 13:08:47

Winners today

1. Liberty Media (LSXMB) – 11.38%

The Liberty SiriusXM Group, through its subsidiaries, engages in the entertainment business in the United States and Canada. It features music, sports, entertainment, comedy, talk, news, traffic, weather channels, podcast, and infotainment services through proprietary satellite radio systems, as well as streamed through applications for mobile and home devices, and other consumer electronic equipment. It also offers connected vehicle services; a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and traffic information services, which provide information as to road closings, traffic flow and incident data to consumers with compatible in-vehicle navigation systems, and real-time weather services in vehicles, boats, and planes. In addition, the company operates a music, comedy, and podcast streaming platform. Further, it offers ad-supported radio services; Pandora Plus, a radio subscription service; and Pandora Premium, an on-demand subscription service. Additionally, the company distributes satellite radios through automakers and retailers, as well as through its website. As of December 31, 2021, it served approximately 34.0 million subscribers through Sirius XM and approximately 6.4 million subscribers through Pandora. The Liberty SiriusXM Group is headquartered in Englewood, Colorado. The Liberty SiriusXM Group is a subsidiary of Liberty Media Corporation.

NASDAQ ended the session with Liberty Media rising 11.38% to $46.01 on Friday while NASDAQ slid 0.52% to $11,226.36.

Earnings Per Share

As for profitability, Liberty Media has a trailing twelve months EPS of $-2.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.51%.

Revenue growth

The year-on-year revenue growth was 4.4%. 8.92B is the current trailing month.

Volatility

Liberty Media’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.80%, a positive 1.96%, and a positive 2.42%.

Liberty Media’s highest amplitude of average volatility was 2.80% (last week), 3.08% (last month), and 2.42% (last quarter).

More news about Liberty Media.

2. Acorda Therapeutics (ACOR) – 7.6%

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

NASDAQ ended the session with Acorda Therapeutics rising 7.6% to $0.62 on Friday, after two successive sessions in a row of gains. NASDAQ slid 0.52% to $11,226.36, after two successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Acorda Therapeutics has a trailing twelve months EPS of $-8.219.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.93%.

Annual Top and Bottom Value

At 16:32 EST Acorda Therapeutics’ stock was valued at $0.62, which is $0.2 less than its 52 week high of $3.10 but still higher than its low 52-week of $0.26.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 124.06M for the twelve trailing months.

Volume

Today’s last reported volume for Acorda Therapeutics is 127497 which is 96.75% below its average volume of 3932880.

Moving Average

Acorda Therapeutics’s value is much higher than its $50-day moving mean of $0.52, and far below its $200-day moving median of $0.87.

More news about Acorda Therapeutics.

3. Coupons.com (COUP) – 6.38%

Coupa Software Incorporated offers a cloud-based platform for managing business spending that links its customers to suppliers around the world. It provides companies with visibility and control of how they spend money and optimize their supply chains. The platform also helps them manage liquidity and achieve profitability savings. The platform provides procurement, expense management and payment solutions. It also offers specialized solutions such as strategic sourcing and contingent workforce management. The platform is available to businesses across a variety of industries including retail, finance, manufacturing and healthcare. Its platform is marketed mainly through direct sales. Coupa Software Incorporated, which was founded in 2006, is located in San Mateo in California.

NASDAQ ended the session with Coupons.com rising 6.38% to $62.69 on Friday while NASDAQ slid 0.52% to $11,226.36.

Earnings Per Share

As for profitability, Coupons.com has a trailing twelve months EPS of $-2.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.29%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 67.7% and a negative 63.2%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Coupons.com’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 786.59M for the twelve trailing months.

More news about Coupons.com.

4. TherapeuticsMD (TXMD) – 5.94%

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD jumping 5.94% to $4.46 on Friday while NASDAQ dropped 0.52% to $11,226.36.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be overbought (>=80).

Sales Growth

TherapeuticsMD saw a 8.6% increase in sales for the current quarter, and 3.6% the following.

More news about TherapeuticsMD.

5. Celsius Holdings (CELH) – 5.12%

Celsius Holdings, Inc. produces, markets, distributes, sells and services liquid supplements and functional drinks in North America, Europe, Asia, the Middle East, and beyond. Under the CELSIUS Originals brand, it offers a variety of carbonated and uncarbonated functional energy beverages; dietary supplements in carbonated flavours, such as apple jack’d and orangesicle; tangerine grapefruit and jackfruit; and functional energy drinks that contain branched chain amino acids and fuel muscle recovery under CELSIUS BCCA+ENERGY. CELSIUS ON-the-GO, which is a powdered version of active ingredients found in functional energy beverages, can be purchased in On-The-Go containers and individual packets. There are also sparkling grapefruit, cucumber lime and orange pomegranate as well as non-carbonated functional drinks such as CELSIUS sweetened, pineapple coconut and watermelon. Direct-to-store distribution distributors distribute its products. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings jumping 5.12% to $109.24 on Friday while NASDAQ dropped 0.52% to $11,226.36.

Earnings Per Share

As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.11.

PE Ratio

Celsius Holdings has a trailing twelve months price to earnings ratio of 993.09. Meaning,
the purchaser of the share is investing $993.09 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.63%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Celsius Holdings’s stock is considered to be oversold (<=20).

Moving Average

Celsius Holdings’s value is way above its 50-day moving average of $91.54 and way higher than its 200-day moving average of $74.46.

Volume

Celsius Holdings’s latest reported volume is 1135240, which is 5.7% below the average of 1204350.

Volatility

Celsius Holdings’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.59%, a positive 0.59%, and a positive 3.36%.

Celsius Holdings’s highest amplitude of average volatility was 1.76% (last week), 3.38% (last month), and 3.36% (last quarter).

More news about Celsius Holdings.

6. Biolase (BIOL) – 4.64%

BIOLASE Inc. and its subsidiaries develop, market, sell, and distribute laser systems to dental professionals and patients across the United States. The company’s laser systems enable dentists and periodontists to use their dental instruments for a variety of procedures. These include complex, cosmetic and restorative surgeries. Waterlase, a all-tissue laser system for the cutting of soft and hard tissue; diode lasers for soft tissues, pain therapy and teeth whitening; and Epic Hygiene laser for non-surgical periodontitis management and clinical production. The company also produces and sells accessories and consumables for laser systems. It also markets flexible fibers, hand pieces and gel kits. It sells products via its distributor network and field sales team. The original name of the company was BIOLASE Technology, Inc., but it changed its name in 2012 to BIOLASE, Inc. BIOLASE, Inc. was established in 1984. It is located in Foothill Ranch, California.

NASDAQ ended the session with Biolase jumping 4.64% to $1.01 on Friday, after three consecutive sessions in a row of losses. NASDAQ fell 0.52% to $11,226.36, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Biolase has a trailing twelve months EPS of $-2.337.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.88%.

More news about Biolase.

7. Atlantic American Corporation (AAME) – 4.56%

Atlantic American Corporation, through its subsidiaries, provides life and health, and property and casualty insurance products in the United States. The company operates through American Southern and Bankers Fidelity segments. It offers property and casualty insurance products, including business automobile insurance coverage for state governments, local municipalities, and other motor pools and fleets; and inland marine and general liability insurance products. The company also provides surety bond coverage for subdivision construction, school bus contracts, as well as performance and payment bonds. In addition, the company provides individual and group whole life insurance, as well as medicare supplement and other accident and health insurance products. It markets its products through independent agents and brokers. The company was founded in 1937 and is headquartered in Atlanta, Georgia.

NASDAQ ended the session with Atlantic American Corporation jumping 4.56% to $2.98 on Friday while NASDAQ slid 0.52% to $11,226.36.

Earnings per Share

Atlantic American Corporation’s trailing twelve-month EPS is $0.14.

PE Ratio

Atlantic American Corporation’s trailing 12 months earnings to price ratio is 21.28. The purchaser of the shares is therefore investing $21.28 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is an indicator of the business’ profitability relative to shareholders’ equity, was 2.64%.

Moving Average

Atlantic American Corporation’s value is higher than its 50-day moving average of $2.91 and higher than its 200-day moving average of $2.89.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6%, now sitting on 192.35M for the twelve trailing months.

More news about Atlantic American Corporation.

8. Canopy Growth (CGC) – 4.43%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth rising 4.43% to $3.66 on Friday, after two consecutive sessions in a row of gains. NASDAQ slid 0.52% to $11,226.36, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings per Share

Canopy Growth’s trailing 12 months profit per share is $-5.239

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a business relative shareholder equity, was negative at -8.84%.

More news about Canopy Growth.

9. Allegiant Travel Company (ALGT) – 4.42%

Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited-frequency, nonstop flights between under-served cities and leisure destinations. As of February 14, 2022, it operated a fleet of 110 Airbus A320 series aircraft. The company also provides air-related services and products in conjunction with air transportation, including baggage fees, advance seat assignments, travel protection products, priority boarding, a customer convenience fee, food and beverage purchases on board, and other air-related services, as well as use of its call center for purchases. In addition, it offers third party travel products, such as hotel rooms and ground transportation, such as rental cars and hotel shuttle products; and air transportation services through fixed fee agreements and charter service on a year-round and ad-hoc basis. Further, the company operates a golf course. Allegiant Travel Company was founded in 1997 and is based in Las Vegas, Nevada.

NASDAQ ended the session with Allegiant Travel Company rising 4.42% to $80.62 on Friday while NASDAQ slid 0.52% to $11,226.36.

Earnings per Share

Allegiant Travel Company’s trailing 12 months profit per share is $2.44

PE Ratio

Allegiant Travel Company’s trailing 12 months price-to-earnings ratio is 33.04. The purchaser of the shares is therefore investing $33.04 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -3.3%.

More news about Allegiant Travel Company.

10. Amedisys (AMED) – 4.32%

Amedisys, Inc. and its affiliates provide healthcare services in the United States. The company operates in three main segments, Home Health, Hospice and Personal Care. Home Health offers services to patients recovering from surgeries, chronic disabilities, or terminal illnesses. It also prevents hospital readmissions by providing skilled nurses. Rehabilitation therapists are specialized in speech, physical, and occupational therapy. Social workers and other aides assist patients. Hospice provides support and comfort for people who have a terminal illness such as heart disease, cancer, lung disease or Alzheimer’s. Patients can receive assistance with daily activities through the Personal Care segment. The company operated 320 home-care centers and 180 hospice care centres in the United States. It also had 14 personal care care centers. This was as of the 31st of December 2020. Amedisys, Inc., was founded in 1982. It is located in Baton Rouge, Louisiana.

NASDAQ ended the session with Amedisys jumping 4.32% to $91.25 on Friday while NASDAQ dropped 0.52% to $11,226.36.

Earnings Per Share

As for profitability, Amedisys has a trailing twelve months EPS of $6.06.

PE Ratio

Amedisys has a trailing twelve months price to earnings ratio of 15.06. Meaning,
the purchaser of the share is investing $15.06 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.91%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.8%, now sitting on 2.21B for the twelve trailing months.

Volume

Today’s last reported volume for Amedisys is 384633 which is 12.35% below its average volume of 438876.

More news about Amedisys.

Losers Today

1. ARC Group Worldwide (ARCW) – -9.57%

ARC Group Worldwide, Inc. provides metal injection molding components in the United States and internationally. The company also offers plastic injection molding and tooling products. It serves aerospace, automotive, defense, medical, and other industries. The company was founded in 1987 and is based in Deland, Florida.

NASDAQ ended the session with ARC Group Worldwide dropping 9.57% to $0.85 on Friday, following the last session’s downward trend. NASDAQ fell 0.52% to $11,226.36, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, ARC Group Worldwide has a trailing twelve months EPS of $-0.225.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -78.48%.

More news about ARC Group Worldwide.

2. Bilibili (BILI) – -7.15%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, and live broadcasting. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili sliding 7.15% to $12.33 on Friday, following the last session’s upward trend. NASDAQ slid 0.52% to $11,226.36, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-1.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.85%.

Sales Growth

Bilibili’s sales growth is 10.7% for the ongoing quarter and 10% for the next.

More news about Bilibili.

3. AngioDynamics (ANGO) – -7.04%

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

NASDAQ ended the session with AngioDynamics dropping 7.04% to $13.61 on Friday, following the last session’s downward trend. NASDAQ slid 0.52% to $11,226.36, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings per Share

AngioDynamics’ trailing twelve-month EPS is $-4.43.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -7.67%.

Moving Average

AngioDynamics is worth less than its $50-day average moving average $16.12 or its $200-day moving median of $20.24.

Annual Top and Bottom Value

AngioDynamics shares are valued at $13.61 as of 16:33 EST. This is way lower than its 52-week peak of $30.00, and higher than its 52 week low of $12.87.

Volume

The current reported AngioDynamics volume is 274678, which is 28.29% lower than its average volume (38355).

More news about AngioDynamics.

4. Futu Holdings (FUTU) – -6.51%

Futu Holdings Limited is an online broker and wealth management company in Hong Kong. It offers trading, clearing and settlement services, margin financing, securities lending and services for stock yield enhancement. The company also provides online wealth management services through Futumoney Plus’ Futubull platform and its moomoo platform. These platforms provide access to mutual funds and private bonds, market data, information services, and NiuNiu community, where clients and users can share their insights and ask questions. The company also offers initial public offering subscriptions and employee share options plan solutions to corporate clients. Futu Holdings Limited, which was established in 2007, is located in Hong Kong.

NASDAQ ended the session with Futu Holdings sliding 6.51% to $52.71 on Friday, after two consecutive sessions in a row of gains. NASDAQ slid 0.52% to $11,226.36, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Futu Holdings has a trailing twelve months EPS of $1.3.

PE Ratio

Futu Holdings has a trailing twelve months price to earnings ratio of 40.61. Meaning,
the purchaser of the share is investing $40.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.51%.

More news about Futu Holdings.

5. Credit Suisse Group (CS) – -6.27%

Credit Suisse Group AG, together with its subsidiaries, provides various financial services in Switzerland, Europe, the Middle East, Africa, the Americas, and Asia Pacific. The company offers wealth management solutions, including investment advice and discretionary asset management services; risk management solutions, such as managed investment products; and wealth planning, succession planning, and trust services. It also provides financing and lending solutions, including consumer credit and real estate mortgage lending, real asset lending relating to ship, and aviation financing for UHNWI; standard and structured hedging, and lombard lending solutions, as well as collateral trading services; and investment banking solutions, such as global securities sales, trading and execution, capital raising, and advisory services. In addition, the company offers banking solutions, such as payments, accounts, debit and credit cards, and product bundles; asset management products; equity and debt underwriting, and advisory services; cash equities, equity derivatives, and convertibles, as well as prime services; and fixed income products, such as credit, securitized, macro, emerging markets, financing, structured credit, and other products. Further, it provides HOLT, a framework for assessing the performance of approximately 20,000 companies; and equity and fixed income research services. The company serves private and institutional clients; ultra-high-net-worth individuals, high-net-worth individuals, and affluent and retail clients; corporate clients, small and medium-sized enterprises, external asset managers, financial institutions, and commodity traders; and pension funds, hedge funds, governments, foundations and endowments, corporations, entrepreneurs, private individuals, financial sponsors, and sovereign clients. As of December 31, 2021, it operated through a network of 311 offices and branches. The company was founded in 1856 and is based in Zurich, Switzerland.

NYSE ended the session with Credit Suisse Group falling 6.27% to $3.59 on Friday while NYSE jumped 0.39% to $15,605.67.

Earnings per Share

Credit Suisse Group’s trailing 12 months EPS is $0.49.

PE Ratio

Credit Suisse Group’s trailing 12-month price-earnings ratio is 7.33. The purchaser of the shares is therefore investing $7.33 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a company, was negative at -7.81%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Credit Suisse Group’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 29.7%, now sitting on 18.08B for the twelve trailing months.

More news about Credit Suisse Group.

6. Assembly Biosciences (ASMB) – -5.59%

Assembly Biosciences, Inc. is a US-based biotechnology company that operates in clinical stages. It develops oral therapies for the treatment and prevention of hepatitis B viral (HBV). Vebicorvir, which can be used to treat chronic HBV infections; ABI H2158, which has been in Phase II clinical trial for chronic HBV infections; and ABI H3733, that is currently in Phase Ia clinical trials for HBV treatment. There are collaboration agreements between the company and Allergan Pharmaceuticals International Limited, BeiGene, Ltd., and Arbutus Biopharma Corporation. Additionally, strategic licensing agreements have been made with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. The company also has a clinical cooperation agreement with Antios Therapeutics, Inc. for the evaluation of a triple combination therapy in chronic hepatitis B infection patients. The original name of the company was Ventrus Biosciences, Inc., but it changed its name in June 2014 to Assembly Biosciences, Inc. Assembly Biosciences, Inc. is located in South San Francisco, California. It was established in 2005.

NASDAQ ended the session with Assembly Biosciences sliding 5.59% to $1.35 on Friday while NASDAQ fell 0.52% to $11,226.36.

Earnings per Share

Assembly Biosciences’ trailing 12 months profit per share was $-1.754

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -71.18%.

Volume

Assembly Biosciences’s current reported volume is 157445, which is 31.6% less than its average volume (2228742).

Yearly Top and Bottom Value

Assembly Biosciences’s stock is valued at $1.35 at 16:34 EST, way below its 52-week high of $2.45 and way above its 52-week low of $1.20.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 14.6% and a negative 21.1%, respectively.

Moving Average

Assembly Biosciences’s value is way under its 50-day moving average of $1.60 and way under its 200-day moving average of $1.84.

More news about Assembly Biosciences.

7. Astrotech Corporation (ASTC) – -5.58%

Astrotech Corporation is a global science and technology commercialization and development company. The company operates in three segments: Astrotech Technologies, Inc. (1st Detect Corporation 1st Detect) and AgLAB Inc. (AgLAB). The ATI segment licenses the AMS Technology platform mass spectrometry technique and owns it. 1. Detect manufactures explosives as well as narcotics trace detections that can be used at borders, secure facilities and airports. The segment produces TRACER 1000 which is a mass-spectrometer-based explosives trace detection to replace explosives detectors at borders, airports and cargo facilities. AgLAB is a segment of AgLAB that develops AgLAB 1000, which is a mass-spectrometer designed for the cannabis and hemp markets. BreathTest 1000, which is a tool that analyzes the breath for volatile organic compound and metabolites in breaths of people, was also developed by AgLAB. The original name of the company was SPACEHAB, Inc., but it changed its name in 2009 to Astrotech Corporation. Astrotech Corporation was founded in 1984 and is located in Austin, Texas.

NASDAQ ended the session with Astrotech Corporation sliding 5.58% to $0.34 on Friday, after three sequential sessions in a row of losses. NASDAQ dropped 0.52% to $11,226.36, after two sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings per Share

Astrotech Corporation’s trailing twelve-month EPS is $-0.167.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -16.02%.

Moving Average

Astrotech Corporation is worth less than its moving average for 50 days of $0.41, and much lower than its moving average for 200 days of $0.52.

Yearly Top and Bottom Value

Astrotech Corporation’s stock is valued at $0.34 at 16:34 EST, way under its 52-week high of $0.83 and above its 52-week low of $0.32.

Revenue growth

The year-on-year revenue growth fell by 79.7%. We now have 720k in the 12 trailing months.

Volume

Astrotech Corporation’s latest reported volume is 1017510, which is 251.03% more than its average volume (2289663).

More news about Astrotech Corporation.

8. Momo (MOMO) – -5.41%

Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. It operates Momo platform that includes its Momo mobile application, as well as various related properties, features, functionalities, tools, and services. The company's Momo mobile application connects people and facilitates interactions based on location and interests; and various recreational activities, including live talent shows, short videos, and social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke, and user participated reality shows. It also operates Tantan, a social and dating application, which enables users to find and establish romantic connections, and meet interesting people; and provides live video, quick chat, value-added, mobile marketing, and other services, as well as mobile games and audio chatrooms. In addition, it allows its platform's users to livestream a variety of content and activities that comprise talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Momo sliding 5.41% to $4.90 on Friday while NASDAQ fell 0.52% to $11,226.36.

Earnings Per Share

As for profitability, Momo has a trailing twelve months EPS of $1.492.

PE Ratio

Momo has a trailing twelve months price to earnings ratio of 3.28. Meaning,
the purchaser of the share is investing $3.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.23%.

Yearly Top and Bottom Value

Momo’s stock is valued at $4.90 at 16:34 EST, way under its 52-week high of $13.99 and way above its 52-week low of $4.09.

More news about Momo.

9. JD.com (JD) – -5.32%

JD.com, Inc. provides supply chain-based technologies and services in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, books, automobile accessories, apparel and footwear, bags, and jewelry. It also provides online marketplace services for third-party merchants; marketing services; and omni-channel solutions to customers and offline retailers, as well as online healthcare services. In addition, the company develops, owns, and manages its logistics facilities and other real estate properties to support third parties; and provides asset management services for logistics property investors. Further, it provides integrated data, technology, business, and user management industry solutions to support the digitization of enterprises and institutions. The company was formerly known as 360buy Jingdong Inc. and changed its name to JD.com, Inc. in January 2014. JD.com, Inc. was incorporated in 2006 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with JD.com falling 5.32% to $49.48 on Friday, following the last session’s upward trend. NASDAQ dropped 0.52% to $11,226.36, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings per Share

JD.com’s trailing 12 months profit per share is $4.89.

PE Ratio

JD.com’s trailing 12-month price-earnings ratio is 10.11. The purchaser of the shares is therefore investing $10.11 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -3.22%.

More news about JD.com.

10. Zai Lab (ZLAB) – -4.97%

Zai Lab Limited is a company that develops and markets therapies for oncology and autoimmune disorders. It also has a focus in neuroscience. Zejula is a once daily small-molecule, poly polymerase 1/2 inhibitor. Optune delivers treatment fields to tumors. NUZYRA treats skin structures and acute bacterial infections. Qinlock can treat gastrointestinal tumors. Odronextamab is also developed to treat diffuse large B cell lymphoma and other types of B-cell lymphomas. Repotrectinib (a tyrosinekinase inhibitor) targets ROS1 or TRK A/B/C for patients who have been treated with TKI. Margetuximab can be used to treat breast cancer and stomach cancer. Adagrasib treats KRAS G12C-mutated NSCLC. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited, a Shanghai-based company was established in 2013.

NASDAQ ended the session with Zai Lab falling 4.97% to $31.72 on Friday while NASDAQ dropped 0.52% to $11,226.36.

Earnings per Share

Zai Lab’s trailing twelve-month EPS is $-3.46.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability in a business relative shareholder equity, was negative at -36.66%.

More news about Zai Lab.

Stay up to date with our winners and losers daily report